Premium
Adoptive T Cell Immunotherapy for Treatment of Ganciclovir‐Resistant Cytomegalovirus Disease in a Renal Transplant Recipient
Author(s) -
Macesic N.,
Langsford D.,
Nicholls K.,
Hughes P.,
Gottlieb D. J.,
Clancy L.,
Blyth E.,
Micklethwaite K.,
Withers B.,
Majumdar S.,
Fleming S.,
Sasadeusz J.
Publication year - 2015
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.13023
Subject(s) - medicine , ganciclovir , cytomegalovirus , immunotherapy , transplantation , immunology , glomerulopathy , valganciclovir , thrombotic microangiopathy , salvage therapy , disease , human cytomegalovirus , herpesviridae , immune system , virus , viral disease , chemotherapy , kidney , glomerulonephritis
Cytomegalovirus (CMV) is a significant cause of morbidity, mortality and graft loss in solid organ transplantation (SOT). Treatment options for ganciclovir‐resistant CMV are limited. We describe a case of ganciclovir‐resistant CMV disease in a renal transplant recipient manifested by thrombotic microangiopathy‐associated glomerulopathy. Adoptive T cell immunotherapy using CMV‐specific T cells from a donor bank was used as salvage therapy. This report is a proof‐of‐concept of the clinical and logistical feasibility of this therapy in SOT recipients.